Skip to main content
Clinical Trials/NCT06650670
NCT06650670
Terminated
Not Applicable

Randomized, Double-blind, Controlled Nutritional Intervention Study of Parallel Groups to Evaluate the Effect of Consuming a Bioactive Compound (EPP) on Joint Health in Healthy Adults

Biosearch S.A.1 site in 1 country37 target enrollmentDecember 1, 2022
ConditionsKnee Discomfort

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Knee Discomfort
Sponsor
Biosearch S.A.
Enrollment
37
Locations
1
Primary Endpoint
KOOS test total score.
Status
Terminated
Last Updated
last year

Overview

Brief Summary

The objective of this trial is to determine the efficacy of oral administration of a bioactive compound (EPP) in healthy individuals with mild knee joint discomfort.

Detailed Description

It is estimated that the incidence of osteoarthritis (OA) is increasing exponentially worldwide, with serious consequences, not only on the quality of life and functionality of the subjects, but also a high burden on the social and health care systems of the countries. Existing treatments for OA are either invasive, and therefore risky for the subject and high cost, or have side effects and cannot be maintained over time. Therefore, there is a high demand to find effective and safe therapies to prevent and/or treat OA, such as functional ingredients or compounds present in food. In this regard, our experimental bioactive compound has been developed and shown to be safe and effective in reducing joint pain and improving quality of life in a previous study. The aim of this study is to evaluate the effect of the consumption of our bioactive compound, in healthy Spanish individuals with mild joint discomfort in the knee.

Registry
clinicaltrials.gov
Start Date
December 1, 2022
End Date
December 15, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Biosearch S.A.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy participants (men and women) between 35 and 65 years of age with knee discomfort.
  • Mild knee joint pain (visual analog scale between 3 and 6 cm).

Exclusion Criteria

  • People with clinical osteoarthritis or any other degenerative joint disease.
  • Persons receiving treatment with anti-inflammatory or chondroprotective drugs (chondroitin sulfate, glucosamine, HA, diacerein) two weeks prior to screening.
  • Persons receiving intra-articular injections in the knee joint in the 3 months prior to the study.

Outcomes

Primary Outcomes

KOOS test total score.

Time Frame: 12 weeks

Using of the KOOS (Knee Injury \& Osteoarthritis Outcomes) Questionnaire.

Secondary Outcomes

  • KOOS Subscales score (pain, symptoms, daily activity, sport and quality of life).(12 weeks)
  • VPS scale for knee pain (general and after physical tests performed at the visits).(12 weeks)
  • Objective assessment of physical activity.(12 weeks)
  • Range of motion of the knee joint.(12 weeks)
  • Changes observed between baseline and final MRI.(12 weeks)
  • Lower body strength and power.(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials